Truqap is a kinase inhibitor that works by blocking pathways that aid the cancer cells survive and improve, so cuts down most cancers advancement. Truqap is from a category of medicines known as an AKT inhibitor. Truqap gained FDA acceptance on November 17, 2023, right after positive final results through https://enzalutamide24679.izrablog.com/35243004/new-step-by-step-map-for-trastuzumab-deruxtecan